secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001493152-26-005702
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa reports extended survival in ovarian cancer CAR-T trial; regulatory approval for 100x dose escalation
--------------------------------------------------------------------------------

- 12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.
- No dose-limiting toxicities; protocol amended to escalate from 1x10^7 to up to 1x10^9 cells/kg (100x increase).
- Next cohort includes lymphodepletion to potentially enhance CAR-T efficacy in solid tumors.
- Three patients remain alive at 15, 14, and 8 months post-treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315226005702/0001493152-26-005702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315226005702/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-005702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer